{"id":"NCT00763815","sponsor":"Sanofi","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","officialTitle":"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2011-06","completion":"2011-06","firstPosted":"2008-10-01","resultsPosted":"2016-10-11","lastUpdate":"2016-11-28"},"enrollment":484,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus Type 2"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":["OptiClik®"]},{"type":"DRUG","name":"Pioglitazone","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Lixisenatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment, followed by an extension.\n\nThe primary objective is to assess the effects of lixisenatide when added to pioglitazone on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.\n\nSecondary objectives are to assess the effects of lixisenatide when added to pioglitazone on the percentage of patients reaching HbA1c less than 7 percent (%) and less than or equal to 6.5%, fasting plasma glucose (FPG), body weight, beta-cell function (assessed by homeostatic model assessment of beta-cell function \\[HOMA-beta\\]), and on fasting plasma insulin (FPI), to assess the safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.","primaryOutcome":{"measure":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.34,"sd":0.1},{"arm":"Lixisenatide","deltaMin":-0.9,"sd":0.089}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":29},"locations":{"siteCount":150,"countries":["United States","Austria","Canada","France","Germany","Greece","Guatemala","India","Mexico","Peru","Puerto Rico","Romania","Turkey (Türkiye)"]},"refs":{"pmids":["23627775"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":161},"commonTop":["Nausea","Nasopharyngitis","Headache","Upper respiratory tract infection","Diarrhoea"]}}